CA3114021C - METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE - Google Patents
METHODS OF TREATMENT FOR ALZHEIMER'S DISEASEInfo
- Publication number
- CA3114021C CA3114021C CA3114021A CA3114021A CA3114021C CA 3114021 C CA3114021 C CA 3114021C CA 3114021 A CA3114021 A CA 3114021A CA 3114021 A CA3114021 A CA 3114021A CA 3114021 C CA3114021 C CA 3114021C
- Authority
- CA
- Canada
- Prior art keywords
- beta
- hydroxypropyl
- cyclodextrin
- cyclodextrin composition
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752131P | 2018-10-29 | 2018-10-29 | |
| US62/752,131 | 2018-10-29 | ||
| US201962885053P | 2019-08-09 | 2019-08-09 | |
| US62/885,053 | 2019-08-09 | ||
| PCT/US2019/057784 WO2020092107A1 (en) | 2018-10-29 | 2019-10-24 | Methods for treating alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3114021A1 CA3114021A1 (en) | 2021-05-07 |
| CA3114021C true CA3114021C (en) | 2025-05-27 |
Family
ID=68583503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3114021A Active CA3114021C (en) | 2018-10-29 | 2019-10-24 | METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11925659B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3873604B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7446322B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210084480A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112996562A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021008139A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3114021C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2992137T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3873604T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020092107A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016276774A1 (en) | 2015-06-10 | 2018-01-18 | Vtesse, Inc. | Hydroxypropyl beta-cyclodextrin compositions and methods |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| US11466008B2 (en) | 2017-09-18 | 2022-10-11 | Eip Pharma, Llc | Co-crystals of neflamapimod (VX-745) |
| AU2020204925B2 (en) | 2019-01-03 | 2025-11-20 | Cyclarity Therapeutics, Inc. | Cyclodextrin dimers, compositions thereof, and uses thereof |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| AU2021284155A1 (en) * | 2020-06-02 | 2023-01-05 | National University Of Singapore | Compositions, their uses in therapy and methods thereof |
| WO2022051631A1 (en) | 2020-09-03 | 2022-03-10 | University Of Notre Dame Du Lac | Therapy to stimulate hippocampal neural progenitors and adult neurogenesis |
| CA3200988A1 (en) * | 2020-11-06 | 2022-05-12 | John Jahangir Alam | Treatment of gait dysfunction in neurodegenerative disease |
| WO2022099094A1 (en) * | 2020-11-06 | 2022-05-12 | Eip Pharma, Inc. | Compositions and methods for treating depression |
| WO2022197640A1 (en) * | 2021-03-14 | 2022-09-22 | Massachusetts Institute Of Technology | Apoe4 impairs myelination via altered cholesterol biosynthesis and transport in neuronal cells |
| EP4433828A1 (en) * | 2021-11-18 | 2024-09-25 | Vib Vzw | Improved gamma-secretase inhibitor screening assays |
| JP2025506676A (ja) | 2022-02-18 | 2025-03-13 | ベレン セラピューティクス ピー.ビー.シー. | ヒドロキシプロピル-ベータ-シクロデキストリンの組成物及びその精製方法 |
| WO2023191425A1 (ko) * | 2022-03-28 | 2023-10-05 | 주식회사 비엔에이치리서치 | 약물의 전기생리학적 스크리닝 방법 |
| CN114569742B (zh) * | 2022-05-09 | 2022-07-19 | 北京剂泰医药科技有限公司 | 一种组合物及其制备方法和应用 |
| KR20250024808A (ko) * | 2022-06-13 | 2025-02-19 | 베렌 테라퓨틱스 피.비.씨. | 하이드록시프로필-베타-사이클로덱스트린 제조를 위한 시스템 및 방법 |
| CA3263540A1 (en) * | 2022-07-29 | 2024-02-01 | Anavex Life Sciences Corp. | Compositions and methods for the prevention of cognitive decline caused by degenerative diseases |
| US20260124236A1 (en) * | 2022-09-30 | 2026-05-07 | Cyclo Therapeutics, Inc. | Methods for treating early alzheimer’s disease |
| WO2025214478A1 (zh) * | 2024-04-12 | 2025-10-16 | 北京华昊中天生物医药股份有限公司 | 一种优替德隆药物组合物及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3346123A1 (de) | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| US4877778A (en) | 1987-07-01 | 1989-10-31 | The Children's Medical Center Corporation | Method of enhancing lipophile transport using cyclodextrin derivatives |
| US5569756A (en) | 1995-03-21 | 1996-10-29 | American Maize-Products Company | Purification of chemically modified cyclodextrins |
| US8883494B2 (en) | 2003-11-14 | 2014-11-11 | Adil A. KHAN | In vitro model for neuronal death |
| KR101530050B1 (ko) | 2007-03-02 | 2015-06-22 | 주식회사 노브메타파마 | 알츠하이머 질환 및 치매를 치료하기 위한 조성물 및 방법 |
| WO2013155485A2 (en) | 2012-04-13 | 2013-10-17 | Alessia Fornoni | Method of using cyclodextrin |
| CA2880880C (en) | 2012-08-03 | 2021-01-26 | John Mckew | Cyclodextrin for the treatment of lysosomal storage diseases |
| FR3014694B1 (fr) * | 2013-12-13 | 2016-11-11 | Roquette Freres | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl |
| KR20170012555A (ko) * | 2014-06-12 | 2017-02-02 | 더 유니버시티 오브 노트르 담 듀락 | 신경 질환 및 대뇌 상해의 치료를 위한 조성물 및 방법 |
| WO2016168772A1 (en) | 2015-04-17 | 2016-10-20 | Sens Research Foundation, Inc. | Cyclodextrin compounds for the prevention and treatment of aging |
| AU2016276774A1 (en) | 2015-06-10 | 2018-01-18 | Vtesse, Inc. | Hydroxypropyl beta-cyclodextrin compositions and methods |
| EP3432880A4 (en) * | 2016-03-20 | 2019-12-11 | Asdera LLC | USE OF CYCLODEXTRINS TO REDUCE ENDOCYTOSIS IN MALIGNES AND NEURODEEGENERATIVE DISEASES |
-
2019
- 2019-10-24 EP EP19805439.7A patent/EP3873604B1/en active Active
- 2019-10-24 JP JP2021547654A patent/JP7446322B2/ja active Active
- 2019-10-24 US US17/289,137 patent/US11925659B2/en active Active
- 2019-10-24 WO PCT/US2019/057784 patent/WO2020092107A1/en not_active Ceased
- 2019-10-24 BR BR112021008139-9A patent/BR112021008139A2/pt unknown
- 2019-10-24 KR KR1020217013055A patent/KR20210084480A/ko not_active Ceased
- 2019-10-24 CA CA3114021A patent/CA3114021C/en active Active
- 2019-10-24 ES ES19805439T patent/ES2992137T3/es active Active
- 2019-10-24 CN CN201980071651.0A patent/CN112996562A/zh active Pending
- 2019-10-24 PT PT198054397T patent/PT3873604T/pt unknown
-
2024
- 2024-01-29 US US18/425,707 patent/US20240415871A1/en not_active Abandoned
-
2025
- 2025-06-09 US US19/232,726 patent/US20250302864A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2992137T3 (es) | 2024-12-09 |
| US20240415871A1 (en) | 2024-12-19 |
| EP3873604A1 (en) | 2021-09-08 |
| US11925659B2 (en) | 2024-03-12 |
| BR112021008139A2 (pt) | 2021-08-03 |
| JP7446322B2 (ja) | 2024-03-08 |
| CA3114021A1 (en) | 2021-05-07 |
| JP2022509358A (ja) | 2022-01-20 |
| EP3873604B1 (en) | 2024-08-21 |
| WO2020092107A1 (en) | 2020-05-07 |
| PT3873604T (pt) | 2024-10-22 |
| US20220008453A1 (en) | 2022-01-13 |
| KR20210084480A (ko) | 2021-07-07 |
| CN112996562A (zh) | 2021-06-18 |
| US20250302864A1 (en) | 2025-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11925659B2 (en) | Methods for treating Alzheimer's disease | |
| US20250114330A1 (en) | (3ar)-1,3a,8-trimethyl-1 ,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration | |
| HK1242998A1 (zh) | 治疗法布里病的给药方案 | |
| CA2988529A1 (en) | Hydroxypropyl beta-cyclodextrin compositions and methods | |
| KR20150002681A (ko) | App 특이적 bace 억제제(asbi) 및 이의 용도 | |
| Rainov et al. | Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? | |
| EP3445369B1 (en) | Vx-745 for use in the treatment of dementia | |
| TW202425995A (zh) | 減少與神經退化疾病相關的神經退化的方法 | |
| WO2024073409A1 (en) | Methods for treating early alzheimer's disease | |
| HK40059055B (en) | Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin | |
| HK40059055A (en) | Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin | |
| Budhwani et al. | Exosome-mediated delivery of a PLD1 modulator overcomes bioavailability hurdles to target synaptopathy in neurodegenerative diseases | |
| CA3268619A1 (en) | Methods for treating early alzheimer's disease | |
| WO2015198329A1 (en) | Injectable formulations for intrathecal administration of antibiotic agents | |
| NZ615726B2 (en) | Dosing regimens for the treatment of fabry disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220923 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241018 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241018 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241018 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED Effective date: 20250306 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250306 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250306 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20250327 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20250425 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250425 |
|
| Q17 | Modified document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED Effective date: 20250521 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE Effective date: 20250527 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251017 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251017 |